Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
223
resultados
Última actualización
18/08/2026 [06:57:00]
Resumen de: KR20200036122A
The present invention relates to a body attachment unit for continuous blood glucose measurement. According to the present invention, a body attachment unit is manufactured in an assembled state in an applicator to minimize extra additional work so that the body attached unit can be attached to a body only by simply operating the applicator. In particular, the body attached unit can be simply and easily used without additional work of connecting an extra transmitter by having a wireless communication chip to communicate with an external terminal. Maintenance of the body attached unit can also be more easily performed. In addition, the body attached unit can be operated by the operation of a user once the body attached unit is attached to the body of the user, and an operation start time point can be adjusted to an appropriate time point as needed. Therefore, the body attached unit can be operated in a more stabilized state to measure blood glucose more accurately.
Resumen de: US20260232213A1
0000 A pulsewave velocity detection device provides a photodiode capable of detecting light transmission between 600-700 nm and 880-940 nm and a light emitting diode capable of transmitting the same. An optical isolation spacer separates the photodiode and the LED. A main control chip provides processing of collected pulsewave velocity signal detection by measuring with the photodetector. A microcontroller thereby calculates local metabolic rate, blood flow volume, Hb concentration, oxygen saturation, and corrected blood glucose and correlates a corrected blood glucose value to the calculated local metabolic rate, blood flow volume, Hb concentration, and oxygen saturation. The instant abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.
Resumen de: US20260232717A1
0000 The invention relates to a terminally heat-sterilized multi-chamber container for parenteral nutrition, comprising a first chamber containing a macronutrient formulation and a second chamber comprising a vitamin B12 formulation, wherein the vitamin B12 formulation (a) is essentially free from glucose, amino acids, vitamin B1, ascorbyl palmitate and/or vitamin C; and (b) stably comprises vitamin B12 for at least 6 months at a temperature of from 1° C. to 40° C. and/or for at least 24 months at a temperature of 25° C.
Resumen de: US20260232736A1
Disclosed herein are methods of treating a subject having diabetes with a population of stem cell-derived islet cells and one or more immunosuppressive reagents, such as an anti-thymocyte globulin binding moiety. The subject may have received an organ transplant.
Resumen de: US20260231913A1
0000 Provided are: a cancer model animal in which a malignant tumor corresponding to a pathological image of human invasive cancer or metastasis has been formed or can be formed, despite the use of transplantation under the skin or into the abdominal cavity; and a method for producing the cancer model animal. One aspect of the present invention is: a cancer model animal in which tumor cells that grow in a culture medium containing L-glucose are transplanted under the skin or into the abdominal cavity; cancer model animal in which tumor cells, such as adenocarcinoma cells, that have been transplanted under the skin or into the abdominal cavity show metastasis; or a cancer model animal in which tumor cells, such as adenocarcinoma cells, that have been transplanted under the skin or into the abdominal cavity show anomaly of function of orthotopic cells.
Resumen de: US20260232230A1
0000 Various systems and methods are disclosed. One or more of the methods disclosed uses machine learning algorithms to predict biophysical responses from biophysical data, such as heart rate monitor data, food logs, or glucose measurements. Biophysical responses may include behavioral responses. Additional systems and methods extract nutritional information from food items by parsing strings containing names of food items.
Resumen de: US20260232202A1
0000 A quick screening method is provided for assessing diabetic foot syndrome for a person. Both feet of the person are positioned onto a testing plate that blocks visible light and permits passage of near infrared (NIR). A multi-spectral camera device is used to simultaneously capture a thermal image and an NIR image of soles of the feet from a side of the testing plate opposite to the feet. The thermal image is aligned with and overlaid onto the NIR image, thereby obtaining an assessment image of the feet. Based on the assessment image, a determination is made regarding whether a temperature difference between a predetermined portion of one foot and a corresponding portion of the other foot exceeds 2.2° C. A potential case of diabetic foot syndrome is reported when the temperature difference exceeds 2.2° C.
Resumen de: US20260232901A1
A system for regulating the concentration of glucose in the blood of a person, comprising: a device for selectively supplying at least one and preferably two substances to said person; at least one and preferably two infusion sets connectable to said device; at least one sensor for measuring a glucose concentration in the blood of said person; a controller for controlling said device such that a certain amount of a said substance is supplied per time unit, wherein said controller is arranged to determine a slope of the measured glucose concentration and if said slope exceeds a first threshold value said controller is arranged to control the device to supply a pre-injection amount of said at least one substance, said pre-injection amount being a percentage of a maximum pre-injection amount, wherein said percentage is dependent on the determined slope.
Resumen de: US20260232232A1
A method and apparatus for analyzing a blood glucose concentration, a device, a storage medium, and a computer program product. The method comprises: acquiring intensity sets corresponding to photoplethysmography pulse wave sets for a target object in a target time period, the intensity set comprising an average alternating-current intensity and an average direct-current intensity; performing curve fitting on the intensity sets to obtain a fitting coefficient and a fitting bias; comparing the fitting bias with a bias range corresponding to the target object, and when it is determined that the fitting bias is not within the bias range, adjusting the fitting bias to obtain an adjusted fitting bias; and performing, on the basis of the adjusted fitting bias, curve fitting on the intensity sets to obtain an adjusted fitting coefficient, and taking the adjusted fitting coefficient as the blood glucose concentration of the target object in the target time period.
Resumen de: US20260232892A1
A system for regulating the concentration of glucose in the blood of a person, comprising: a device for selectively supplying insulin and glucagon; at least two infusion sets; at least one sensor for measuring a glucose concentration in the blood of said person; and a controller for controlling said device such that a certain amount of insulin and glucagon is supplied per time unit, wherein said certain amount is chosen in accordance with the measured glucose concentration as prescribed by an insulin injection curve and a glucagon injection curve, wherein said controller is further arranged to determine if glucagon is supplied to said person in a chosen time frame, and wherein the controller is arranged to re-assess and optionally adjust the insulin injection curve based on the determination if glucagon is supplied to said person in said chosen time frame.
Resumen de: EP4789663A2
Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.
Resumen de: US12702755B1
A system which provides closed loop insulin administration is disclosed. A closed loop insulin administration system which bases insulin administration on accurate glucose measurements may improve a patient's quality of life.
Resumen de: US20260224809A1
0000 In accordance with one aspect, a medication infusion device is provided that includes a patch pump configured to be removably adhered to a wearer's skin for delivering doses of medication (e.g., insulin) from a cartridge (e.g., a pre-filled cartridge) through a transcutaneous portion. The medication infusion system may include a pumping system configured to advance a plunger in the cartridge to cause medication in the cartridge to be delivered to the patient. The pumping mechanism may be an improved system that reduced errors in medication administration.
Resumen de: US20260224172A1
Certain aspects of the present disclosure relate to methods and systems for predicting glycemic events in a patient induced as a result of physical activity. In certain aspects, a method includes monitoring a plurality of analytes of the patient continuously during a time period to obtain analyte data, the plurality of analytes including at least glucose and lactate. The method further includes processing the analyte data from the time period to determine an intensity level of physical activity engaged by the patient during the time period. The method further includes generating a glycemic event prediction using at least the analyte data for the plurality of analytes and the determination of physical activity intensity. The method further includes generating one or more recommendations for treatment for the patient based, at least in part, on the glycemic event prediction.
Resumen de: AU2025206886A1
The present disclosure provides cells that are competitive to cancer cells without starvation and exhaustion even in an environment in which glucose is depleted. More specifically, the present disclosure provides T cells with enhanced glucose uptake ability, wherein the T cells are modified such that the expression of glucose transporters in the T cells is regulated in response to changes in tumor microenvironmental conditions, and/or the T cells comprise a nucleic acid sequence encoding a glucose transporter operably linked to a tumor microenvironment sensing element that senses changes in tumor microenvironmental conditions.
Resumen de: US20260226424A1
0000 The present invention provides a method for washing lymphocytes, including washing lymphocytes with a bicarbonate ion-containing physiological aqueous solution; a method for cryopreserving lymphocytes, including suspending and freezing lymphocytes obtained by the method in a cryopreservation solution containing a physiological aqueous solution; a washing solution for lymphocytes, including a bicarbonate ion-containing physiological aqueous solution; a cryopreservation solution for lymphocytes, containing a bicarbonate ion-containing physiological aqueous solution, dextran, glucose, DMSO, and human serum albumin; a lymphocyte-containing composition, containing lymphocytes treated with a bicarbonate ion-containing physiological aqueous solution and the aforementioned cryopreservation solution; a kit for preparing lymphocytes for transplantation, containing the lymphocyte-containing composition and a diluent for transplantation containing a bicarbonate ion-containing physiological aqueous solution, and the like.
Resumen de: US20260224480A1
A system for oral delivery of an active ingredient is provided, the system including: a mucoadhesive layer including a mucoadhesive and an active ingredient; and a backing layer extending over the mucoadhesive layer, the backing layer including a bulk agent, the active ingredient being selected from the group consisting of nicotine, caffeine, anatabine, at least one cannabinoid such as tetrahydrocannabinol, and a combination thereof, the system being orally dissolvable, and the bulk agent being selected from the group consisting of at least one mono-, di-, and/or polysaccharide, at least one sugar alcohol, and a combination thereof.
Resumen de: AU2026206162A1
A glucose monitoring system, comprising: a glucose sensor comprising a portion configured to be positioned in a body of a user in fluid contact with a bodily fluid to sense glucose in the bodily fluid; and sensor electronics coupled to the glucose sensor, the sensor electronics comprising: one or more processors, memory coupled with the one or more processors, and wireless communication circuitry configured to communicate data indicative of glucose levels based on the sensed glucose in the bodily fluid according to a Bluetooth communication protocol; and a reader device comprising: a display; one or more processors; a transceiver configured to receive the data indicative of the glucose levels; a memory coupled to the one or more processors of the reader device and storing instructions that when executed by the one or more processors of the reader device cause the one or more processors of the reader device to: determine a glucose curve based on the data indicative of the glucose levels, wherein the glucose curve is associated with a glucose response to an event, calculate a numerical score for the event, wherein the numerical score is based in part on an area under the glucose curve and a duration of the glucose response to the event, determine a cumulative score comprising a sum of the numerical scores associated with a plurality of events, and output on the display the cumulative score and a target score. ul u l
Resumen de: US20260224136A1
0000 An example continuous glucose monitor includes a printed circuit board (“PCB”) having first and second outer layers and an inner layer; a semiconductor package having a plurality of pins coupled to the first outer layer of the PCB; an electrical contact formed on the second outer layer of the PCB; a trace having a first portion disposed on the first outer layer, a second portion disposed on the inner layer, and a third portion disposed on the second outer layer, the trace having a first end coupled to a first pin of the plurality of pins and a second end coupled to the electrical contact; and an encapsulant disposed around a perimeter of the semiconductor package, the encapsulant covering the plurality of pins, the first portion of the sensor trace, the third portion of the sensor trace, wherein an upper surface of the semiconductor package remains exposed.
Resumen de: AU2025207075A1
The present disclosure provides cells that are competitive with respect to cancer cells, without experiencing starvation or exhaustion, even in glucose-depleted environments. Specifically, the present disclosure provides survivor T cells with enhanced glucose uptake capacity. The T cells are modified so as to express a glucose transporter and/or configured such that the expression of a glucose transporter is enhanced. Also provided are a cell population including such cells, a pharmaceutical composition, and a treatment method.
Resumen de: US20260224811A1
The ambulatory infusion pump system of claim 17, wherein the infusion pump does not include a display and includes a bolus button configured to enable programming of a predetermined amount of medicament, and wherein the at least one processor is configured to disable the bolus button when the higher priority interface or lower priority interface has been accessed.The ambulatory infusion pump system of claim 11, wherein the at least one processor is further configured to cause a message to display on the lower priority interface indicating that the lower priority interface is inaccessible due to the higher priority interface having been accessed.The ambulatory infusion pump system of claim 11, wherein the at least one processor is configured to automatically exit the lower priority interface if the lower priority interface is active when the higher priority interface is accessed.In an infusion pump system that includes a pump that may have a user interface for pump programming, one or more smartphones or other remote control devices that interface with the infusion pump, and/or an automated insulin delivery algorithm, there is a potential conflict between commands such as boluses being programmed on multiple devices and/or calculated by the AID algorithm at the same time. In order to avoid low glucose levels that could result from delivering multiple boluses from these various sources when only one bolus is needed, systems and methods disclosed herein provide a bolus permissio
Resumen de: AU2026206210A1
A continuous glucose measurement apparatus is provided. The continuous glucose measurement apparatus comprises a body attachable unit configured to be inserted into and attached to a body and to measure blood glucose. The body attachable unit comprises: a sensor module including a sensing area formed at an end portion of the sensor module, and a guide needle configured to cover at least a partial area of the sensor module and to move integrally with the sensor module into the body. The guide needle comprises an incision portion formed at a front end portion of the guide needle to incise skin of the body, and an insertion support portion extending from a back portion of the incision portion. In a state in which the body attachable unit is inserted into the body, a depth of an incised portion formed by the insertion support portion of the guide needle is less than an insertion depth of the sensor module. The sensing area is disposed in a region corresponding to the incision portion of the guide needle. ul u l
Resumen de: WO2026161967A1
A pharmaceutical composition co-formulating insulin and C-peptide for simultaneous delivery to restore physiological coordination is described. The invention is based on the discovery, validated by advanced artificial intelligence (AI) modeling, that C-peptide acts on at least three distinct receptors (the Insulin Receptor, GPR146, and RXFP1) to potentiate insulin signaling, terminate pro-metabolic signals that lead to hypercortisolemia and dyslipidemia, and activate anti-fibrotic pathways. This approach is supported by a model of an integrated hormonal network where the relaxin, C-peptide, and cortisol systems are interwoven through central neuroendocrine modulation, direct molecular crosstalk, and metabolic convergence. These coordinated mechanisms provide comprehensive diabetes management beyond glucose control. The co-formulation is approximately 7-fold more mass-efficient than insulin monotherapy. Furthermore, the invention provides a dual-mechanism neuroprotective therapy for Alzheimer's disease by inhibiting amyloid-beta production in neurons and promoting its clearance by microglia via a novel neuro-immune pathway.
Resumen de: WO2026164338A1
Provided are a method and an electronic device, the method comprising: acquiring blood glucose information of a user from a continuous blood glucose monitoring device; displaying a user interface including a plurality of objects; changing a specific time indicated by an indicator in response to user interaction with the indicator; and displaying a fifth object for inputting an event in response to user interaction with an input component.
Nº publicación: WO2026164339A1 06/08/2026
Solicitante:
SD BIOSENSOR INC [KR]
SD BIOSENSOR, INC.
Resumen de: WO2026164339A1
A method and an electronic device are provided, the method comprising: acquiring blood glucose information of a user from a continuous blood glucose monitoring device; displaying a user interface including a plurality of objects; changing a specific time indicated by an indicator in response to user interaction with the indicator; displaying a fifth object for inputting an event in response to user interaction with an input component; and storing or transmitting to an external electronic device at least one of a first object, a second object, and a third object in response to user interaction with a fourth object.
BOPI
Sede Electrónica
